Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines

Shellard, Sharon A.; Fichtinger-Schepman, A.M.; Lazo, John S.; Hill, Bridget T.

doi:10.1097/00001813-199308000-00011

Cited by 55 publications

(31 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tyrosine kinase inhibitors (TKIs) are also frequently used, but platinum-based therapy remains the best option for the treatment of advanced NSCLC when the mutation status of the epidermal growth factor receptor (EGFR) is unknown (Bidoli et al, 2007;Jemal et al, 2009;Vilmar and Sørensen, 2009;National Comprehensive Cancer Network, 2011). However, the development of platinum-based therapies has slowed and many NSCLC patients derived little therapeutic benefit from any of those currently available (Shellard et al, 1993;Pfister et al, 2004;Wang et al, 2011). Seeking an optimal prognostic biomarker for clinical efficacy of platinum-based treatment remains a hotspot in this field.…”

Section: Introductionmentioning

confidence: 99%

XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies

Chen

Zhao

Shi

et al. 2012

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Abstract:Objective: XRCC1 polymorphism is a research hotpot in individual treatment for non-small cell lung cancer (NSCLC). To obtain the association between XRCC1 polymorphism and clinical outcome of platinum-based treatment for NSCLC, a meta-analysis was conducted. Methods: Databases including PubMed, Embase, Cochrane, and Chinese National Knowledge Infrastructure (CNKI) were searched for publications that met the inclusion criteria. A fixed effect model was used to estimate pooled odds ratio (OR) and hazard ratio (HR) with 95% confidence interval (CI) for the association between XRCC1 Arg399Gln and response or survival of platinum-based treatment for advanced NSCLC. A chi-squared-based Q-test was used to test the heterogeneity hypothesis. Egger's test was used to check publication bias. Results: Seventeen published case-control studies that focus on the association between XRCC1 Arg399Gln and response or survival of platinum-based treatment for advanced NSCLC in 2 256 subjects were included in this meta-analysis, of whom 522 were AA genotypes (23.2% frequency), 916 AG genotypes (40.6% frequency), and 818 GG genotypes (36.2% frequency). The overall response rate (ORR) was 45.2% (110/243) for AA genotype patients, 29.9% for AG genotype (73/244), and 30.7% for GG genotype (124/403). The heterogeneity test did not show any heterogeneity and the Egger's test did not reveal an obvious publication bias among the included studies. The meta-analysis indicated that AA genotype patients presented higher response rates toward platinum drug treatment compared with G model (GG+GA) patients (GG vs. AA model: OR=0.489, P=0.021; AG vs. AA model: OR=0.608, P=0.026; GA+AA vs. GG model: OR=1.259, P=0.135; GG+GA vs. AA model: OR=0.455, P=0.0001). However, no evidence validates XRCC1 associates with the survival following platinum drug therapy. Conclusions: Our meta-analysis suggested that XRCC1 Arg399Gln is related with the sensitivity of NSCLC patients to platinum-based treatment. AA genotype patients present more desirable curative effectiveness compared with other patients.

show abstract

Section: Introductionmentioning

confidence: 99%

XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies

Chen

Zhao

Shi

et al. 2012

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

show abstract

“…Platinum causes platinum-DNA adducts that block transcription, leading to cytotoxicity and cell death, whereas increased removal of platinum from cancer cells and repair of platinum-DNA adducts by tolerance mechanisms induce drug resistance. 1 Therefore, efficient DNA repair can modulate platinum cytotoxicity and its anticancer efficacy. [2][3][4][5] Among DNA repair pathways, nucleotide excision repair (NER) is an important mechanism underlying cisplatin resistance by removing platinum-DNA interstrand adducts.…”

Section: Introductionmentioning

confidence: 99%

DNA Repair Capacity in Peripheral Lymphocytes Predicts Survival of Patients With Non–Small-Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy

Wang

Yin

Dong

et al. 2011

JCO

View full text Add to dashboard Cite

A B S T R A C T PurposePlatinum-based regimens are the standard chemotherapy for patients with advanced non-smallcell lung cancer (NSCLC). DNA repair capacity (DRC) in tumor cells plays an important role in resistance to platinum-based drugs. We have previously reported that efficient DRC, as assessed by an in vitro lymphocyte-based assay, was a determinant of poor survival in patients with NSCLC in a relatively small data set. In this larger independent study of 591 patients with NSCLC, we further evaluated whether DRC in peripheral lymphocytes predicts survival of patients with NSCLC who receive platinum-based chemotherapy. Patients and MethodsAll patients were recruited at The University of Texas MD Anderson Cancer Center and donated blood samples before the start of any chemotherapy. We measured DRC in cultured T lymphocytes by using the host-cell reactivation assay, and we assessed associations between DRC in peripheral lymphocytes and survival of patients with NSCLC who were treated with first-line platinum-based chemotherapy. ResultsWe found an inverse association between DRC in peripheral lymphocytes and patient survival. Compared with patients in the low tertile of DRC, patients with NSCLC in the high tertile of DRC had significantly worse overall and 3-year survival (adjusted hazard ratio [HR], 1.33; 95% CI, 1.04 to 1.71; P ϭ .023; and HR, 1.35; 95% CI, 1.04 to 1.76; P ϭ .025, respectively). This trend was more pronounced in patients with early-stage tumors, adenocarcinoma, or squamous cell carcinoma. ConclusionWe confirmed that DRC in peripheral lymphocytes is an independent predictor of survival for patients with NSCLC treated with platinum-based chemotherapy.

show abstract

“…The development of resistance to cisplatin at a cellular level is believed to be a major obstacle to improving the outcome with cisplatin-based chemotherapy. Experimental models of cisplatin resistance have implicated multiple mechanisms including decreased drug accumulation, elevated glutathione and metallothionein levels, increased DNA repair and increased tolerance of DNA damage (Andrews and Howell, 1990;Shellard et al, 1993).…”

mentioning

confidence: 99%

Ormaplatin resistance is associated with decreased accumulation of its platinum (II) analogue, dichloro(D,L-trans)1,2-diaminocyclohexaneplatinum (II)

Rischin

Ling²

1996

Br J Cancer

View full text Add to dashboard Cite

Summary Ormaplatin (also known as tetraplatin) is a platinum-containing analogue which has recently undergone clinical trials. Ormaplatin may undergo conversion to dichloro(D,L-trans)-1,2-diaminocyclohexaneplatinum(II) [PtCl2(trans-dach)]. The cisplatin-resistant murine lymphoma cell lines E8 and E5, were found to be cross-resistant to ormaplatin and PtCl2(trans-dach). We found an inverse rank correlation between drug resistance and drug accumulation for PtCl2(trans-dach) similar to our previous findings with cisplatin; however, accumulation of ormaplatin in the resistant cells was increased. Ormaplatin cytotoxicity appears to result primarily from extracellular conversion to PtCl2(trans-dach), since ormaplatin cytotoxicity was decreased under conditions where extracellular conversion to PtCl2(trans-dach) was minimised. Co-incubation with different inhibitors of energy metabolism resulted in a 65-70% increase in PtCl2(trans-dach) accumulation in the parental cell line Ri.1 and a 113-307% increase in the resistant cell line E5 which suggests that the decrease in accumulation in E5 may be at least partly energy dependent. We conclude from these findings that crossresistance to ormaplatin is associated with an energy-dependent decreased accumulation of PtCl2(trans-dach) in these cisplatin-resistant cell lines.

show abstract

Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines

Cited by 55 publications

References 0 publications

XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies

XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies

DNA Repair Capacity in Peripheral Lymphocytes Predicts Survival of Patients With Non–Small-Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy

Ormaplatin resistance is associated with decreased accumulation of its platinum (II) analogue, dichloro(D,L-trans)1,2-diaminocyclohexaneplatinum (II)

Contact Info

Product

Resources

About